Related Experiment Video
Updated: Aug 15, 2026
11:12
Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material
Published on: August 1, 2018
[A plea for selective use of the MammaPrint test]
M de Boer1, A C Voogd, V C G Tjan-Heijnen
1Maastricht Universitair Medisch Centrum, afd. Interne Geneeskunde, onderafd. Medische Oncologie en Onderzoeksinstituut GROW, Maastricht.
Nederlands Tijdschrift Voor Geneeskunde
|April 13, 2017
Summary
The MammaPrint test may help avoid chemotherapy for some high-risk breast cancer patients. However, clinical factors alongside genomic risk should guide treatment decisions for optimal patient outcomes.
Area of Science:
- Oncology
- Genomics
- Clinical Trials
Background:
- The MINDACT study evaluated the MammaPrint genomic test for breast cancer treatment decisions.
- Chemotherapy use is often based on clinical risk assessment, but genomic profiling offers additional insights.
Purpose of the Study:
- To critically evaluate the MammaPrint test's role in guiding chemotherapy decisions for high-risk breast cancer patients.
- To propose an integrated approach combining genomic and clinical factors for personalized treatment strategies.
Main Methods:
- Analysis of MINDACT study results.
- Utilizing the New Adjuvant Online tool to calculate chemotherapy survival benefits.
- Comparison of genomic risk (MammaPrint) with clinical factors (tumor size, nodal status, grade).
Main Results:
- The MammaPrint test identified approximately 50% of clinically high-risk patients as genomic low-risk, potentially avoiding chemotherapy.
- A significant proportion of clinically high-risk patients may not benefit from chemotherapy based on genomic assessment.
Conclusions:
- Chemotherapy decisions in breast cancer should integrate both MammaPrint genomic results and clinical parameters.
- The use of MammaPrint should be considered for patients with a calculated 10-year survival benefit from chemotherapy between 2-4%.
